Please use this identifier to cite or link to this item:
Title: Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.
Austin Authors: Straus, David;Collins, Graham;Walewski, Jan;Zinzani, Pier Luigi;Grigg, Andrew P ;Sureda, Anna;Illes, Arpad;Kim, Tae Min;Alekseev, Sergey;Specht, Lena;Buccheri, Valeria;Younes, Anas;Connors, Joseph;Forero-Torres, Andres;Fenton, Keenan;Gautam, Ashish;Purevjal, Indra;Liu, Rachael;Gallamini, Andrea
Affiliation: Memorial Sloan Kettering Cancer Center, New York City, NY, USA
Clinical Haematology
Oxford Cancer and Hematology Center, Churchill Hospital, Oxford, UK
BC Cancer Centre for Lymphoid Cancer, Vancouver, Canada
Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warsaw, Poland
Institute of Hematology Seragnoli, University of Bologna, Bologna, Italy
Institut Català d'Oncologia-Hospitalet, Hospital Quirón Dexeus, Barcelona, Spain
University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Seoul National University Hospital, Seoul, Republic of Korea
Petrov Research Institute of Oncology, St. Petersburg, Russia
Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Hematology Service, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
Memorial Sloan Kettering Cancer Center, New York City, NY, USA
Seattle Genetics, Bothell, WA, USA
Millennium Pharmaceuticals, Cambridge, MA, USA
Research and Clinical Innovation, Antoine-Lacassagne Cancer Center, Nice, France
Issue Date: 25-Dec-2020
Date: 2020-08-25
Publication information: Leukemia & Lymphoma 2020; 61(12): 2931-2938
Abstract: We investigate the impact of granulocyte-colony stimulating factor (G-CSF) primary prophylaxis (G-PP, N = 83) versus no G-PP (N = 579) on safety and efficacy of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) in the ECHELON-1 study of previously untreated stage III/IV classical Hodgkin lymphoma. G-PP was associated with lower incidence of ≥ grade 3 neutropenia (29% versus 70%) and febrile neutropenia (11% versus 21%). Fewer dose delays (35% versus 49%), reductions (20% versus 26%), and hospitalizations (29% versus 38%) were observed. Seven neutropenia-associated deaths occurred in the A + AVD arm; none received G-PP. A + AVD with G-PP was associated with decreased risk of a modified progression-free survival event by 26% compared with A + AVD alone (95% CI: 0.40-1.37). G-PP reduced the rate and severity of adverse events, including febrile neutropenia, reduced treatment delays, dose reductions, and discontinuations, and may thus improve efficacy outcomes. These data support G-PP for all patients treated with A + AVD.
DOI: 10.1080/10428194.2020.1791846
ORCID: 0000-0001-6033-4510
Journal: Leukemia & Lymphoma
PubMed URL: 32842815
Type: Journal Article
Subjects: Hodgkin lymphoma
brentuximab vedotin
frontline therapy
growth factor
primary prophylaxis
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 19, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.